Characteristics and management of follicular events and contact dermatitis in patients using tapinarof cream for the treatment of atopic dermatitis or plaque psoriasis
Open Access
- 2 July 2025
- journal article
- review article
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 36 (1) , 2517388
Abstract
Purpose: Provide insights into the incidence, pre-sentation and management of follicular events and contact dermatitis in patients with plaque psoriasis or atopic dermatitis (AD) treated with tapinarof cream 1%. Materials and methods: Key clinical trial publications for tapinarof were reviewed and augmented with the authors' opinions based on real-world clinical experience. Results: In the PSOARING and ADORING trials, discontinuation rates due to follicular events and contact dermatitis were low and most patients did not require dose modifications or treatment interruptions. In our experience, which includes the use of tapinarof in combination with other agents, tapinarof is generally well tolerated and if events of folliculitis or contact dermatitis occur, patients can be advised to temporarily discontinue application on affected sites until the event resolves, continuing application to other affected areas and body regions. Education on the correct application of tapinarof is important in the management of psoriasis and AD. Conclusions: Tapinarof is a novel topical treatment option for adults with plaque psoriasis and patients with AD, with no restrictions regarding application sites and duration of use. Follicular events and contact dermatitis associated with tapinarof treatment are generally mild and self-limiting and rarely interfere with therapy. Clinicaltrials.gov numbers: NCT05014568, NCT05032859, NCT05142774, NCT03956355, NCT03983980, NCT04053387.Keywords
This publication has 18 references indexed in Scilit:
- Maximal Usage Trial of Tapinarof Cream 1% Once Daily in Pediatric Patients Down to 2 Years of Age with Extensive Atopic DermatitisAmerican Journal of Clinical Dermatology, 2025
- Tapinarof cream 1% once daily: Significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trialsJournal of the American Academy of Dermatology, 2024
- Tapinarof Cream 1% Once Daily for the Treatment of Plaque Psoriasis: Case Photography of Clinical Outcomes from Three Phase 3 TrialsDermatology and Therapy, 2023
- Tapinarof cream 1% once daily for the treatment of plaque psoriasis: Patient-reported outcomes from the PSOARING 3 trialJournal of the American Academy of Dermatology, 2023
- One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: Results from the PSOARING 3 trialJournal of the American Academy of Dermatology, 2022
- Tapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and PharmacokineticsAmerican Journal of Clinical Dermatology, 2021
- Tapinarof-associated folliculitis is generally mild, self-limiting, and rarely interferes with therapyJournal of the American Academy of Dermatology, 2021
- Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor–modulating agentJournal of the American Academy of Dermatology, 2021
- Phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of plaque psoriasisJournal of the American Academy of Dermatology, 2019
- A phase 2, randomized dose-finding study of tapinarof (GSK2894512 cream) for the treatment of atopic dermatitisJournal of the American Academy of Dermatology, 2019